Meta-analysis of 5 RCTs in 717 nicotine users aged 12–26: varenicline increased abstinence versus placebo, bupropion or nicotine patch (RR 1.99, 95% CI 1.04–3.80); safety was comparable to placebo for treatment-emergent adverse events.
Meta-analysisn = 717
Park et al. Varenicline for nicotine cessation in youth: A meta-analysis of randomized controlled trials addressing FDA labeling gaps in age and product use